EU H2020 Project "MECADISTEM (A new and innovative method to extract adipose Stromal Vascular Fraction:..)": description, partecipants, costs and EC-fundings

#	Pagina
attuale pagina	/open-h2020/projects/223875/index.html
-1	/open-h2020/projects/218546/index.html
-2	/open-h2020/projects/217717/index.html
-3	/open-h2020/projects/193771/index.html
-4	/open-fp7/projects/185605/index.html

MECADISTEM project word cloud

Explore the words cloud of the MECADISTEM project. It provides you a very rough idea of what is the project "MECADISTEM" about.

efficient once frequent ed urologists tools stemcis treat single tissues cure time market validated damages cell dysfunction view extract clinical expecting shown surgeons quality tissue point proven radical million people filtration preclinical commercial treatment therapies secure extracted cellular methodology avoiding svf adipose gain simply complication patients profits kit stem milestones progenitor unmet operations substantial medical cells hire prostatectomy form enzymatic fraction roi mechanically enzymes erectile isolate regenerating digestion repair hold 12 collagenase life alternatives prostate feasibility finalise men candidate constraints centrifugation rp grinding imposed adult damaged post savings 28 surgical impairs stromal mecadistem vascular preparation minutes money cancer financial

Project "MECADISTEM" data sheet

The following table provides information about the project.

Coordinator	STEMCIS SAS Organization address address: 2 RUE MAXIME RIVIERE city: SAINTE CLOTILDE postcode: 97490 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Project website	http://www.stemcis.com
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-SMEInst-2018-2020-1
Funding Scheme	SME-1
Starting year	2019
Duration (year-month-day)	from 2019-05-01 to 2019-08-31

#	participants	country	role	EC contrib. [€]
1	STEMCIS SAS	FR (SAINTE CLOTILDE)	coordinator	50˙000.00

STEMCIS SAS

FR (SAINTE CLOTILDE)

coordinator

50˙000.00

Project objective

Erectile dysfunction (ED) is a significant and common medical problem which impairs quality of life of men and their partners. ED is a frequent complication after a radical prostatectomy (RP) due to surgical treatment for prostate cancer. For this condition, ED represents a significant unmet medical need, since there is no efficient treatment to repair the cellular damages following a RP. Clinical implementation of stem cell treatment represents a potential candidate for ED treatment after RP. Adult progenitor cells extracted from adipose tissue, called Stromal Vascular Fraction (SVF) have shown promising results in preclinical and clinical studies to treat post-RP ED. STEMCIS has developed a unique kit to isolate the adipose cells which hold the potential to cure post-prostatectomy ED by regenerating the damaged tissues. MECADISTEM comes in the form of a single-use kit that includes all the tools necessary to simply and rapidly (less than 30 minutes) extract adipose tissue progenitor cells mechanically (grinding, centrifugation, filtration). Compared to the state-of-the-art alternatives using “collagenase (enzymatic) digestion”, MECADISTEM does not require the use of enzymes, avoiding the problems and constraints imposed by the use of this enzymatic digestion and offering substantial time and money savings, on both technical and surgical operations. Having validated this methodology in preclinical study, this project is planned to finalise the development and market preparation of this kit. In this Phase 1 Feasibility Study, we aim to evaluate the main milestones of the project from a technical, commercial and financial point of view. Once in the market, MECADISTEM will be used by urologists and surgeons to cure ED in patients following a RP, where the current therapies have not been proven effective. It will secure the growth for STEMCIS, expecting to gain over €12 million in profits, hire 6 new people and reach a ROI of €6.28 from this project after 5 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MECADISTEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MECADISTEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)